GlassScriptPhysician profile
Eli Maggie Figueroa
NPI 1144513102
$4,415.95
in general payments reported to CMS, 2019-2025
21 companies · $494 in 2025
The $494 reported for 2025 was more than what 92% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $1,491 · 2023: $1,524 · 2024: $142 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,310.01 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Jazz Pharmaceuticals INC. | $550.09 | 2022-2025 | |
| Neurelis, INC. | $452.00 | 2021-2023 | Valtoco |
| Aquestive Therapeutics, INC. | $427.22 | 2021-2025 | |
| Corium, LLC | $349.69 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $228.28 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $192.89 | 2021-2023 | Qelbree |
| Sumitomo Pharma America, INC. | $156.83 | 2023 | Aptiom |
| Sunovion Pharmaceuticals INC. | $117.18 | 2021-2022 | |
| Livanova USA, INC. | $108.03 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Aprecia Pharmaceuticals, LLC | $76.86 | 2022-2023 | Spritam |
| Catalyst Pharmaceuticals, INC. | $75.88 | 2023-2024 | Fycompa |
| Biocodex, INC. | $71.55 | 2023 | Diacomit |
| Biohaven Pharmaceuticals, INC. | $67.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.18 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $58.42 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $42.29 | 2025 | Motpoly Xr |
| Tris Pharma INC | $23.75 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $18.56 | 2021 | |
| Cranial Technologies, INC | $14.86 | 2023 | Doc Band |
| Amneal Pharmaceuticals LLC | $14.60 | 2023 | Lyvispah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.